New cancer drugs are very expensive – here’s how we work out value for our money

The remit of the PBS is to provide access to effective and safe pharmaceuticals at a price that provides value for money to the Australian taxpayer. It decides which new drugs it will subsidise based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). But how does the PBAC assess value for money?

Read more in The Conversation – value for money, by Prof Jon Karnon, Dr Hossein Haji Ali Afzalis and Dr Laura Edney.

This entry was posted in Public Health and tagged , , , , , . Bookmark the permalink.

Comments are closed.